Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Huihong You"'
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 1469K, Different ABL TKIs demonstrate potency differences in relative cellular and biochemical target inhibition (S1); Incomplete restoration of BCR-ABL signaling activity following washout of dasatinib or ponatinib tracks with intracellul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45bb2f349dbdbd12daa46b5865710272
https://doi.org/10.1158/0008-5472.22396247
https://doi.org/10.1158/0008-5472.22396247
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 337K, Summary of mean fluorescence intensity values for levels of CrkL and STAT5 phosphorylation in K562 cells following acute ABL TKI exposure followed by standard and expanded washout (S1); Kinase:inhibitor dissociation off-rates for ABL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464ff7a97c638799f3fd2f9fd2378704
https://doi.org/10.1158/0008-5472.22396238.v1
https://doi.org/10.1158/0008-5472.22396238.v1
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 45K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2e7b60dba00e64f41fe83e32b81c9f
https://doi.org/10.1158/0008-5472.22396250.v1
https://doi.org/10.1158/0008-5472.22396250.v1
Autor:
Altomare, Deborah A.1, Huihong You1, Guang-Hui Xiao1, Ramos-Nino, Maria E.2, Skele, Kristine L.1, De Rienzo, Assunta1, Jhanwar, Suresh C.3, Mossman, Brooke T.2, Kane, Agnes B.4, Testa, Joseph R.1 jrtesta@fccc.edu
Publikováno v:
Oncogene. 9/8/2005, Vol. 24 Issue 40, p6080-6089. 10p.
Autor:
Matthew H. Brush, Huihong You, Douglas N. Runckel, Joseph E. Aslan, Robert T. Youker, Laurel Thomas, Robert L. Milewski, Arndt Vogel, Jessica Endig, Hongjun Shu, Gary Thomas, Danielle M. Williamson, Haian Fu, Kam Sprott, Kenneth D. Greis, Yuhong Du, Anthony Possemato
Publikováno v:
Molecular Cell. 34:497-509
TRAIL selectively kills diseased cells in vivo, spurring interest in this death ligand as a potential therapeutic. However, many cancer cells are resistant to TRAIL, suggesting the mechanism mediating TRAIL-induced apoptosis is complex. Here we ident
Autor:
Gary Thomas, Laurel Thomas, Huihong You, Katelyn M. Atkins, Franco Pissani, Robert T. Youker, Melanie J. Harriff
Publikováno v:
Journal of Biological Chemistry. 283:11772-11784
Human immunodeficiency virus, type 1, negative factor (Nef) initiates down-regulation of cell-surface major histocompatibility complex-I (MHC-I) by assembling an Src family kinase (SFK)-ZAP70/Syk-phosphoinositide 3-kinase (PI3K) cascade through the s
Autor:
Michael J. Birrer, Bob G. Sanders, Kimberly Kline, Powel H. Brown, Weiping Yu, Huihong You, Marla Simmons-Menchaca
Publikováno v:
Molecular Carcinogenesis. 22:247-257
We have demonstrated that RRR-α-tocopheryl succinate (10 μg/mL vitamin E succinate (VES) treatment of estrogen receptor–negative MDA-MB-435 human breast cancer cells induces 9, 19, 51, and 72% apoptotic cells on days 1–4, respectively, after tr
Autor:
Kurt W. Vogel, Dennis R. Koop, Lauren T. Adrian, Dorian LaTocha, Ryan MacKenzie, Brian J. Druker, Huihong You, Thomas O'Hare, Jeffrey W. Tyner, Jenny Luo, Bryan D. Marks, Matthew S. Zabriskie, Kara Johnson, Anupriya Agarwal, Steven M. Riddle, Christopher A. Eide, John Apgar, Michael W. Deininger
The imatinib paradigm in chronic myelogenous leukemia (CML) established continuous BCR-ABL inhibition as a design principle for ABL tyrosine kinase inhibitors (TKI). However, clinical responses seen in patients treated with the ABL TKI dasatinib desp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b35458dd3e7d2c4be9b2f453e74d7d
https://europepmc.org/articles/PMC3674150/
https://europepmc.org/articles/PMC3674150/
Appl1 (Adaptor protein containing pleckstrin homology [PH], phosphotyrosine binding [PTB], and Leucine zipper motifs) is an adaptor that participates in cell signaling by interacting with various signaling molecules including Akt, PI3-kinase (PI3K),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6180eac0f42b9b6e3e818f039c2709c7
https://europepmc.org/articles/PMC2944914/
https://europepmc.org/articles/PMC2944914/
Publikováno v:
The Journal of biological chemistry. 285(9)
The adaptor protein APPL1 (adaptor protein containing pleckstrin homology (PH), phosphotyrosine binding (PTB), and leucine zipper motifs) was first identified as a binding protein of AKT2 by yeast two-hybrid screening. APPL1 was subsequently found to